在老年帕金森病患者中,精神饮食的坚持与较低的Zonulin水平有关
Özge Esgin1, Hatice Ayşe Tokçaer Bora2, Özlem Gülbahar3
1Department of Nutrition and Dietetics, Faculty of Health Sciences, Bayburt University, Bayburt, Türkiye.
概括
对MIND饮食的更高坚持与帕金森病 (PD) 的老年人中较低的佐努林水平有关. 这表明MIND饮食可能会支持PD患者的肠道屏障完整性和神经功能.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 胃肠病学 胃肠病学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病.
- 肠道屏障功能障碍和炎症都与PD病变发生有关.
- 佐努林是一种肠道透性的生物标志物.
研究的目的:
- 为了研究MIND饮食的坚持与PD老年人血清佐努林水平之间的关联.
- 探索饮食在调节PD中肠道屏障完整性方面的潜在作用.
主要方法:
- 这是一项涉及57名患有PD的老年人 (Hoehn & Yahr 1-3阶段) 的横截面研究.
- 通过调查 (饮食摄入量,体力活动) 和血液样本收集的数据,用于分析zonulin.
- 使用食物回忆数据评估的MIND饮食坚持.
主要成果:
- 血清佐努林水平与饮食总抗氧化能力负相关 (p < 0.05).
- 在调整后的分析中,更高的MIND饮食坚持与较低的血清松林水平显著相关 (β = -0.25).
结论:
- 研究结果表明,MIND饮食的坚持与PD中降低的佐努林水平之间存在新的关联.
- 在帕金森病中,MIND饮食可能代表一种饮食干预措施,以支持肠道屏障完整性和潜在的神经功能.
相关概念视频
Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708
Neural Regulation
40.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.0K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
Chronic Kidney Disease III: Interprofessional Care
80
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


